Q-omics provides the consensus-scored FAM174C profile across patient tissues and cancer cell-line models. FAM174C expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM174C is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FAM174C RNA expression shows 19,822 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FAM174C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM174C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM174C survival associations across molecular data types. FAM174C RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM174C RNA expression–survival associations across cancer types. High FAM174C expression shows unfavorable associations in ACC, KICH, UCS and LGG, but favorable associations in STAD and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM174C RNA expression.
This table summarizes FAM174C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM174C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM174C shows higher tumor expression in KIRC, COAD, STAD, LIHC, BLCA and LUSC. The KIRC box plot shows higher FAM174C RNA expression in tumor versus normal tissue (log2 FC = +0.942, t-test p < 0.001).
This table shows molecular features associated with FAM174C in patient tissues and cancer cell lines. In patient samples, FAM174C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM174C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
